Policlinica Gipuzkoa S.A.

The trials here

What the 23 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease10 trials
• Parkinson disease10 trials
• Cerebral palsy1 trial
• Dystonia1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Multiple system atrophy1 trial
• Primary biliary cholangitis1 trial

Phase

• Phase 312 trials
• Phase 29 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Active, not recruiting8 trials
• Completed6 trials
• Not yet recruiting5 trials
• Recruiting4 trials

Lead sponsor

• Hoffmann-La Roche7 trials
• F. Hoffmann-La Roche AG2 trials
• AbbVie1 trial
• AriBio Co., Ltd.1 trial
• BioArctic AB1 trial
• and 11 more

Running trials

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease

  2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Recruiting

  Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

  NCT07216235· Phase 3· Zydus Therapeutics Inc.· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  NCT06976203· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Recruiting

  A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

  NCT06680830· Phase 2· Neuron23 Inc.· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)

  2023-506183-13-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· AriBio Co., Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

  NCT04639050· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Eisai Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

  NCT03100149· Phase 2· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease4 recruiting
• Alzheimer disease3 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Primary biliary cholangitis1 recruiting

Closed trials

• Completed

  A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease

  2024-516966-12-00· Phase 2· Novartis Pharma AG· Source

• Completed

  Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

  NCT06671938· Phase 2· BioArctic AB· Source

• Active, not recruiting

  To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

  NCT06553027· Phase 3· Cerevance· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

  NCT05206513· Phase 3· Neurocrine Biosciences· Source

• Completed

  Open-label Trial in Parkinson's Disease (PD)

  NCT04760769· Phase 3· AbbVie· Source